Detailed company information
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q1Released: Apr 27, 2026
Earnings Transcript for 2025 - Q4Released: Feb 24, 2026
Earnings Transcript for 2025 - Q3Released: Oct 29, 2025
Earnings Transcript for 2025 - Q1Released: May 01, 2025
Earnings Transcript for 2024 - Q4Released: Feb 25, 2025
Earnings Transcript for 2024 - Q3Released: Nov 13, 2024
Earnings Transcript for 2024 - Q2Released: Jul 31, 2024
Earnings Transcript for 2024 - Q1Released: May 13, 2024
Earnings Transcript for 2023 - Q4Released: Feb 27, 2024
Earnings Transcript for 2023 - Q3Released: Nov 07, 2023
Earnings Transcript for 2023 - Q2Released: Aug 05, 2023
Earnings Transcript for 2023 - Q1Released: May 15, 2023
Earnings Transcript for 2022 - Q4Released: Mar 10, 2023
Earnings Transcript for 2022 - Q3Released: Nov 12, 2022
Earnings Transcript for 2022 - Q2Released: Aug 11, 2022
Earnings Transcript for 2022 - Q1Released: May 09, 2022
Earnings Transcript for 2021 - Q4Released: Mar 03, 2022
Earnings Transcript for 2021 - Q3Released: Nov 06, 2021
Earnings Transcript for 2021 - Q2Released: Aug 10, 2021
Earnings Transcript for 2021 - Q1Released: May 08, 2021
Earnings Transcript for 2020 - Q4Released: Mar 04, 2021
Earnings Transcript for 2020 - Q3Released: Nov 10, 2020
Earnings Transcript for 2020 - Q2Released: Aug 12, 2020
Earnings Transcript for 2020 - Q1Released: May 13, 2020
Dafinchi
